Compare LODE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | SLGL |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.0M | 247.1M |
| IPO Year | 2004 | 2016 |
| Metric | LODE | SLGL |
|---|---|---|
| Price | $4.29 | $79.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.6M | 28.4K |
| Earning Date | 05-11-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $1,582.85 | N/A |
| Revenue Next Year | $246.20 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $6.96 |
| 52 Week High | $4.98 | $97.97 |
| Indicator | LODE | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 51.77 |
| Support Level | $3.06 | $66.85 |
| Resistance Level | $4.79 | $75.00 |
| Average True Range (ATR) | 0.32 | 5.47 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 53.73 | 42.45 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.